IP Library Granted Patent US 7,077,961
Granted Patent B2
US 7,077,961 · App. 10/203,106 · Granted Jul 18, 2006

Apparatus for extracorporeal blood or plasma treatment comprising a wet semi-permeable membrane and methods for making the same

View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 7,077,961
App. No.
10/203,106
Granted
Jul 18, 2006
Kind
B2
Abstract

The present invention relates to a device for the extracorporeal treatment of blood or plasma, comprising two compartments, one compartment intended for circulating blood or plasma, and one compartment intended for circulating spent liquid, separated by a wet semi-permeable membrane, characterized in that the device has, before and after sterilization, the following technical characteristics: the membrane is impregnated with an aqueous glycerol solution; the aqueous glycerol solution contains from 7% to 15% by weight of glycerol and is free of toxic chemical compounds; the two compartments are purged of the aqueous glycerol solution. The present invention also relates to processes for manufacturing this device.

Claims (27)

1. A process for limiting risks of leakage and variations in a water permeability of a device for the extracorporeal treatment of blood or plasma, said device being subjected to a temperature below 0° C., and comprising, a first compartment configured to circulate blood or plasma, and a second compartment configured to circulate spent liquid, said first and second compartments being separated by a semi-permeable membrane, said semi-permeable membrane being stored in a wet state, said process comprising the steps of:

preparing an aqueous glycerol solution having a concentration of 7% to 15% by weight of glycerol and being free of chemical compounds that are toxic before or after high-energy sterilization;

placing the aqueous glycerol solution in contact with the semi-permeable membrane;

purging the device of the aqueous glycerol solution; and

sterilizing the device with higher energy sterilization.

2. A process according to claim 1 , wherein the step of placing the aqueous glycerol solution in contact with the semi-permeable membrane by circulating the aqueous glycerol solution in the first compartment.

3. A process according to claim 1 , wherein the step of placing the aqueous glycerol solution in contact with the semi-permeable membrane by circulating the aqueous glycerol solution in the second compartment.

4. A process according to claim 1 , wherein the step of placing the aqueous glycerol solution in contact with the semi-permeable membrane by circulating the aqueous glycerol solution in the first compartment and the second compartment.

5. A process according to claim 1 , wherein said high-energy sterilization includes exposure of said aqueous glycerol solution to gamma irradiation.

6. A process for limiting risks of leakage and variations in a water permeability of a device for extracorporeal treatment of blood or plasma, said device being subjected to a temperature below 0° C., and comprising, a first compartment configured to circulate blood or plasma, and a second compartment configured to circulate spent liquid, said first and second compartments being separated by a semi-permeable membrane, said semi-permeable membrane being stored in a wet state, said process comprising the steps of:

preparing a solution having one or more chemical compounds, said one or more chemical compounds improving the biocompatibility of the membrane;

placing said solution in contact with a surface of the membrane, said surface being configured to be placed in contact with blood or plasma;

mounting the membrane with improved biocompatibility in a housing;

preparing an aqueous glycerol solution having a concentration of glycerol from 7% to 15% by weight and being free of chemical compounds that are toxic before or after a high-energy sterilization;

placing the aqueous glycerol solution in contact with the semi-permeable membrane;

purging the device of the aqueous glycerol solution; and

sterilizing the device with higher energy sterilization.

7. A process according to claim 6 , wherein said high-energy sterilization includes exposure of said aqueous glycerol solution to gamma irradiation.

8. A process for limiting risks of leakage and variations in a water permeability of a device for extracorporeal treatment of blood or plasma, said device being subjected to a temperature below 0° C., and comprising, a first compartment configured to circulate blood or plasma, and a second compartment configured to circulate spent liquid, said first and second compartments being separated by a semi-permeable membrane, said semi-permeable membrane being stored in a wet state, said process comprising the steps of:

mounting the membrane in a housing;

preparing a solution having one or more chemical compounds, said compounds improving a biocompatibility of the membrane;

placing said solution in contact with a surface of the membrane, said surface being configured to be placed in contact with blood or plasma;

preparing an aqueous glycerol solution having a concentration of glycerol from 7% to 15% by weight and being free of chemical compounds that are toxic before or after a high-energy sterilization;

placing the aqueous glycerol solution in contact with the semi-permeable membrane;

purging the device of the aqueous glycerol solution; and

sterilizing the device with higher energy sterilization.

9. A process according to claim 8 , wherein said high-energy sterilization includes exposure of said aqueous glycerol solution to gamma irradiation.

Assignments (4)
RELEASE OF SECURITY INTEREST IN PATENTS Recorded Dec 28, 2011
From: CITICORP TRUSTEE COMPANY LIMITED, AS SECURITY AGENT
To: GAMBRO INDUSTRIES SAS
Reel/Frame 027455/0333 →
GAMBRO INDUSTRIES SAS Recorded May 21, 2009
From: GAMBRO INDUSTRIES SAS
To: CITICORP TRUSTEE COMPANY LIMITED
Reel/Frame 022714/0692 →
MERGER Recorded Mar 14, 2006
From: HOSPAL INDUSTRIE SAS
To: GAMBRO INDUSTRIES
Reel/Frame 017624/0704 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Aug 6, 2002
From: THOMAS, MICHEL
To: HOSPAL INDUSTRIE
Reel/Frame 013730/0105 →